Inovalon (INOV) to Acquire Creehan Holding
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Inovalon (NASDAQ: INOV) entered into a definitive agreement to acquire Creehan Holding Co., Inc., the parent company of Creehan & Company, the industry’s leading independent provider of specialty pharmacy and specialty medications management software-as-a-service (SaaS) platforms.
“Specialty pharmacy is a uniquely high-value sub-segment of the healthcare ecosystem that is of increasing importance to payors, pharmaceutical companies, and patients alike,” said Keith Dunleavy, M.D., chief executive officer and chairman of the board of Inovalon. “This complex segment of the market benefits greatly from a data-focused approach as the mutual goal of all parties is to achieve greater quality, outcomes, and financial performance. The clear leadership position of Creehan & Company and the vital nature of this strongly growing market segment, coupled with significant data and technology synergies with Inovalon’s platforms and client base, make this an exciting and powerful combination.”
Critical to the patient, payor, and pharmaceutical company, the market segment known as specialty pharmacy focuses on higher cost and complexity segments of pharmacological care. Driven by accelerating discoveries in pharmacological treatments, the rising number of patients with highly complex and chronic disease conditions, and the increasing application of precision medicine, the U.S. specialty pharmacy market has grown from approximately $98 billion in 2010 to $178 billion in 2015, and is expected to continue to expand to an estimated $282 billion by 20201. All segments of the healthcare ecosystem – payors, providers, pharma, patients, and the elements of their associated care delivery matrix – rely on the capabilities of the specialty pharmacy for their own respective care, quality, regulatory and economic goals.
According to a 2015 report by The Drug Channel Institute, Creehan & Company’s software platform, known as ScriptMed™, is utilized by approximately 30% of the specialty pharmacy market, making it the most widely utilized software within the specialty pharmacy industry. Today Creehan & Company proudly works with many of the nation’s largest health plans, pharmacy benefits management (PBM), retail and specialty pharmacies, and pharmaceutical companies providing and supporting the software enabling their respective specialty pharmacy service needs.
“Creehan & Company and Inovalon share a common philosophy that data, its analysis, and the resulting ability to drive highly meaningful impact is key to the achievement of improved care, quality, and financial performance within the healthcare ecosystem,” said Sean Creehan, chief executive officer of Creehan & Company. “Our combination with Inovalon will enable us to further advance and scale our industry-leading platform and bring an expanded set of capabilities to our existing clients as well as to the expansive client base of Inovalon. All of us at Creehan & Company are excited about the people, technologies, and vision that we have found with Inovalon and see our union as a significant benefit for our clients and competitive advantage unmatched in the industry today.”
Inovalon will acquire Creehan Holding Co., Inc., the parent company of Creehan & Company, for approximately $105 million payable at closing, plus additional contingent payments of up to $25 million based upon the attainment of financial performance objectives through the end of 2018 plus the awarding of certain employee incentive equity amounts subject to vesting requirements. The purchase price will be paid with a combination of available cash and $10 million in restricted stock. The acquisition is subject to customary closing conditions and antitrust clearance and is expected to close on or around October 1, 2016. Creehan & Company had revenues of approximately $27 million in 2015 and has a long track record of strong growth and profitability. The acquisition is part of Inovalon’s previously described utilization of its balance sheet strength for strategic tuck-in acquisitions of industry-leading technologies, was contemplated in its provision of 2016 financial guidance provided on August 3, 2016, as well as the Company’s longer-term 2020 guidance, and therefore results in no change to previously provided 2016 or 2020 financial guidance.
For more information regarding Inovalon’s acquisition of Creehan & Company, a transaction brief has been posted on the Investors section of Inovalon’s website located at investors.inovalon.com.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rite Aid (RAD)/Walgreens (WBA) Antitrust Concerns Doesn't Mean Deal is Dead, Says Deutsche Bank
- HID Global Wins Homeland Security Award from Government Security News
- TransDigm (TDG) Defended at Deutsche Bank
Create E-mail Alert Related CategoriesCorporate News, Mergers and Acquisitions
Related EntitiesDefinitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!